BRAFV600E突变增强了放射性碘治疗的甲状腺乳头状癌基于年龄的预后分层：一项回顾性队列研究

IF 3 3区医学 Q2 ONCOLOGY

Clinical oncology Pub Date : 2025-09-24 DOI:10.1016/j.clon.2025.103945

J. Cao , H. Liang , X. Li , X. Guan , Y.Z. Ma , J. Li

{"title":"BRAFV600E突变增强了放射性碘治疗的甲状腺乳头状癌基于年龄的预后分层：一项回顾性队列研究","authors":"J. Cao , H. Liang , X. Li , X. Guan , Y.Z. Ma , J. Li","doi":"10.1016/j.clon.2025.103945","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate whether BRAF<sup>V600E</sup> mutation status enhances the value of age in predicting clinical outcomes for papillary thyroid carcinoma (PTC) patients receiving radioactive iodide (RAI) therapy.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective analysis of 1160 PTC patients treated with RAI therapy. Patients were stratified by age (≤18, 18-55, and ≥55 years) and BRAF<sup>V600E</sup> status. Clinicopathological characteristics, treatment responses, and risk factors for poor outcomes (biochemical/structural incomplete response biochemical incomplete response/structural incomplete response [BIR/SIR]) were analysed using logistic regression.</div></div><div><h3>Results</h3><div>BRAF<sup>V600E</sup>-positive patients aged ≤18 years showed aggressive features, including larger tumour size, higher lymph node metastasis rates, elevated thyroglobulin levels (TgAb-negative), and worse 6-month/3-year outcomes (all <em>P</em> < .05). Multivariate analysis confirmed high-risk subtypes, distant metastasis, and elevated Tg levels as independent BIR/SIR predictors. BRAF<sup>V600E</sup>-negative patients showed no significant age-related clinical characteristics and outcomes (<em>P</em> > .05).</div></div><div><h3>Conclusion</h3><div>BRAF<sup>V600E</sup> mutation status significantly modifies the impact of age in PTC patients with RAI therapy. Patients aged ≤18 years with BRAF<sup>V600E</sup>-positive exhibit distinct aggressive behaviours and poorer RAI therapy responses. These findings support integrating BRAF<sup>V600E</sup> testing with age stratification to refine risk assessment and therapeutic strategies.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"48 ","pages":"Article 103945"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The BRAFV600E Mutation Enhances Age-Based Prognostic Stratification in Radioiodine-Treated Papillary Thyroid Cancer: A Retrospective Cohort Study\",\"authors\":\"J. Cao , H. Liang , X. Li , X. Guan , Y.Z. Ma , J. Li\",\"doi\":\"10.1016/j.clon.2025.103945\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><div>To evaluate whether BRAF<sup>V600E</sup> mutation status enhances the value of age in predicting clinical outcomes for papillary thyroid carcinoma (PTC) patients receiving radioactive iodide (RAI) therapy.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective analysis of 1160 PTC patients treated with RAI therapy. Patients were stratified by age (≤18, 18-55, and ≥55 years) and BRAF<sup>V600E</sup> status. Clinicopathological characteristics, treatment responses, and risk factors for poor outcomes (biochemical/structural incomplete response biochemical incomplete response/structural incomplete response [BIR/SIR]) were analysed using logistic regression.</div></div><div><h3>Results</h3><div>BRAF<sup>V600E</sup>-positive patients aged ≤18 years showed aggressive features, including larger tumour size, higher lymph node metastasis rates, elevated thyroglobulin levels (TgAb-negative), and worse 6-month/3-year outcomes (all <em>P</em> < .05). Multivariate analysis confirmed high-risk subtypes, distant metastasis, and elevated Tg levels as independent BIR/SIR predictors. BRAF<sup>V600E</sup>-negative patients showed no significant age-related clinical characteristics and outcomes (<em>P</em> > .05).</div></div><div><h3>Conclusion</h3><div>BRAF<sup>V600E</sup> mutation status significantly modifies the impact of age in PTC patients with RAI therapy. Patients aged ≤18 years with BRAF<sup>V600E</sup>-positive exhibit distinct aggressive behaviours and poorer RAI therapy responses. These findings support integrating BRAF<sup>V600E</sup> testing with age stratification to refine risk assessment and therapeutic strategies.</div></div>\",\"PeriodicalId\":10403,\"journal\":{\"name\":\"Clinical oncology\",\"volume\":\"48 \",\"pages\":\"Article 103945\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0936655525002006\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0936655525002006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的评价BRAFV600E突变状态是否增强了年龄在预测接受放射性碘化物（RAI）治疗的甲状腺乳头状癌（PTC）患者临床预后中的价值。材料与方法我们对1160例接受RAI治疗的PTC患者进行回顾性分析。患者按年龄（≤18岁、18-55岁和≥55岁）和BRAFV600E状态进行分层。采用logistic回归分析临床病理特征、治疗反应和不良结局的危险因素（生化/结构不完全缓解生化不完全缓解/结构不完全缓解[BIR/SIR]）。结果≤18岁brafv600e阳性患者表现为肿瘤体积较大、淋巴结转移率较高、甲状腺球蛋白水平升高（tgab阴性）、6个月/3年预后较差（P < 0.05）。多因素分析证实高危亚型、远处转移和Tg水平升高是独立的BIR/SIR预测因子。brafv600e阴性患者无明显的年龄相关临床特征和结局（P > 0.05）。结论brafv600e突变状态显著改变年龄对RAI治疗PTC患者的影响。年龄≤18岁的brafv600e阳性患者表现出明显的攻击行为和较差的RAI治疗反应。这些发现支持将BRAFV600E检测与年龄分层相结合，以完善风险评估和治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The BRAFV600E Mutation Enhances Age-Based Prognostic Stratification in Radioiodine-Treated Papillary Thyroid Cancer: A Retrospective Cohort Study

Aims

To evaluate whether BRAF^V600E mutation status enhances the value of age in predicting clinical outcomes for papillary thyroid carcinoma (PTC) patients receiving radioactive iodide (RAI) therapy.

Materials and methods

We conducted a retrospective analysis of 1160 PTC patients treated with RAI therapy. Patients were stratified by age (≤18, 18-55, and ≥55 years) and BRAF^V600E status. Clinicopathological characteristics, treatment responses, and risk factors for poor outcomes (biochemical/structural incomplete response biochemical incomplete response/structural incomplete response [BIR/SIR]) were analysed using logistic regression.

Results

BRAF^V600E-positive patients aged ≤18 years showed aggressive features, including larger tumour size, higher lymph node metastasis rates, elevated thyroglobulin levels (TgAb-negative), and worse 6-month/3-year outcomes (all P < .05). Multivariate analysis confirmed high-risk subtypes, distant metastasis, and elevated Tg levels as independent BIR/SIR predictors. BRAF^V600E-negative patients showed no significant age-related clinical characteristics and outcomes (P > .05).

Conclusion

BRAF^V600E mutation status significantly modifies the impact of age in PTC patients with RAI therapy. Patients aged ≤18 years with BRAF^V600E-positive exhibit distinct aggressive behaviours and poorer RAI therapy responses. These findings support integrating BRAF^V600E testing with age stratification to refine risk assessment and therapeutic strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical oncology 医学-肿瘤学

CiteScore

5.20

自引率

8.80%

发文量

332

审稿时长

40 days

期刊介绍： Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.